Our team is composed of gastric cancer clinical treatment experts, translational research experts, and basic research experts, and enjoys a high reputation in China. Prof. Lin Shen is the principal investigator of our team, who is the Vice President of Peking University Cancer Hospital and the Vice President of Beijing Institute for Cancer Research, and Director of the Department of Gastrointestinal Oncology at Peking University Cancer Hospital.

    我们的团队由胃癌临床治疗专家、转化研究专家、基础研究专家组成，在国内享有盛誉。 沈琳教授是我们团队的首席研究员，目前担任北京大学肿瘤医院副院长、北京肿瘤研究所副所长，北京大学肿瘤医院消化肿瘤科主任。

    We focus on the accurate treatment of digestive system tumors and multi-disciplinary comprehensive treatment of difficult illness cases, as well as phase I-III clinical trials and preclinical transformation research on new anticancer drugs. Our research covers almost all gastrointestinal tumor types， including gastric cancer, esophageal cancer, colorectal cancer, pancreatic cancer, and gastrointestinal neuroendocrine oncology.

    我们专注于消化系统肿瘤的精准治疗和疑难病例的多学科综合治疗，以及抗癌新药的I-III期临床试验和临床前转化研究。 我们的研究涵盖几乎所有胃肠道肿瘤类型，包括胃癌、食管癌、结直肠癌、胰腺癌和胃肠道神经内分泌肿瘤。

    Due to our outstanding achievements in the field of gastrointestinal tumors, we have received a number of grants from government organizations, non-profit organizations, and pharmaceutical companies. Prof. Shen is the Chief Scientist of National key R & D plan “New Technology for Gastric Cancer Targeted-Therapy” of the Ministry of science and technology, the Key R & D plan “The artificial intelligence study of anti-HER2 therapeutic efficacy in gastric cancer based on multi-omics analysis” of the National Natural Science Foundation of China, and leads 6 national/provincial research projects, over 40 international cooperative projects, and a number of international/domestic multicenter clinical trials. Prof. Shen promoted the establishment of multiple guidelines for the diagnosis and treatment of digestive tract cancer in Asia and China.

    由于在胃肠道肿瘤领域取得了一系列成果，我们获得了来自政府组织、公益组织和制药公司的多项资助。 沈琳教授是科技部国家重点研发计划“胃癌靶向治疗新技术”、重点研发计划“抗HER2治疗效果的人工智能研究”的首席科学家 ，主持国家自然科学基金“基于多组学分析的胃癌研究”，主持国家/省级科研项目6项，国际合作项目40余项，多项国际/国内多中心临床试验。

    We have participated in the clinical research of almost all new drugs/protocols for advanced gastric cancer, and the results directly promote or negate the clinical indications of multiple drugs/protocols. For the advanced gastric cancer with Chinese characteristics that is difficult to treat and backward in targeted therapy, we have constructed a large-scale and real-time mouse xenograft (PDX) model for the first time in the world. These models have been widely used by domestic and foreign pharmaceutical companies for the development and transformation of new drugs research. The research that was based on gastric cancer molecular typing and efficacy prediction markers has been routinely used for clinical guidance of patients' medication and dynamic monitoring of efficacy. Related research can be found in the "Recent Publications" section.

    我们参与了晚期胃癌几乎所有新药/方案的临床研究，结果直接促进或否定了多个药物/方案的临床适应症。针对中国特色的治疗棘手且靶向治疗落后的晚期胃癌，我们在国际上首次构建了大规模实时性小鼠移植瘤(PDX)模型，该模型已被国内外药企广泛用于新药研发及转化研究中。我们建立的基于胃癌分子分型、疗效预测标志物的研究已常规用于临床指导患者用药、疗效动态监测。相关的研究可以在“Recent Publications”部分找到。

• Lu Z, Fang Y, Liu C, Zhang X, Xin X, He Y, Cao Y, Jiao X, Sun T, Pang Y, Wang Y, Zhou J, Qi C, Gong J, Wang X, Li J, Tang L, Shen L. Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial. J Clin Oncol. 2021 Mar 1;39(7):748-756. doi: 10.1200/JCO.20.01254.


• Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, Yu J, Bu Z, Chen L, Du Y, Wang X, Wu A, Li G, Su X, Xiao G, Cui M, Wu D, Chen L, Wu X, Zhou Y, Zhang L, Dang C, He Y, Zhang Z, Sun Y, Li Y, Chen H, Bai Y, Qi C, Yu P, Zhu G, Suo J, Jia B, Li L, Huang C, Li F, Ye Y, Xu H, Wang X, Yuan Y, E JY, Ying X, Yao C, Shen L, Ji J; RESOLVE study group. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021 Aug;22(8):1081-1092. doi: 10.1016/S1470-2045(21)00297-7.


• Xu RH, Zhang Y, Pan H, Feng J, Zhang T, Liu T, Qin Y, Qin S, Yin X, Liu B, Ba Y, Yang N, Voon PJ, Tanasanvimon S, Zhou C, Zhang WL, Shen L. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1015-1024. doi: 10.1016/S2468-1253(21)00313-7.


• Li J, Deng Y, Zhang W, Zhou AP, Guo W, Yang J, Yuan Y, Zhu L, Qin S, Xiang S, Lu H, Gong J, Xu T, Liu D, Shen L. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. J Hematol Oncol. 2021 Jun 21;14(1):95. doi: 10.1186/s13045-021-01095-1.


• Peng Z, Liu T, Wei J, Wang A, He Y, Yang L, Zhang X, Fan N, Luo S, Li Z, Gu K, Lu J, Xu J, Fan Q, Xu R, Zhang L, Li E, Sun Y, Yu G, Bai C, Liu Y, Zeng J, Ying J, Liang X, Xu N, Gao C, Shu Y, Ma D, Dai G, Li S, Deng T, Cui Y, Fang J, Ba Y, Shen L. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun (Lond). 2021 Nov;41(11):1173-1182. doi: 10.1002/cac2.12214.


• Lu Z, Zou J, Li S, Topper MJ, Tao Y, Zhang H, Jiao X, Xie W, Kong X, Vaz M, Li H, Cai Y, Xia L, Huang P, Rodgers K, Lee B, Riemer JB, Day CP, Yen RC, Cui Y, Wang Y, Wang Y, Zhang W, Easwaran H, Hulbert A, Kim K, Juergens RA, Yang SC, Battafarano RJ, Bush EL, Broderick SR, Cattaneo SM, Brahmer JR, Rudin CM, Wrangle J, Mei Y, Kim YJ, Zhang B, Wang KK, Forde PM, Margolick JB, Nelkin BD, Zahnow CA, Pardoll DM, Housseau F, Baylin SB, Shen L, Brock MV. Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature. 2020 Mar;579(7798):284-290. doi: 10.1038/s41586-020-2054-x.


• Xu J, Shen L, Zhou Z, Li J, Bai C, Chi Y, Li Z, Xu N, Li E, Liu T, Bai Y, Yuan Y, Li X, Wang X, Chen J, Ying J, Yu X, Qin S, Yuan X, Zhang T, Deng Y, Xiu D, Cheng Y, Tao M, Jia R, Wang W, Li J, Fan S, Peng M, Su W. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 Nov;21(11):1500-1512. doi: 10.1016/S1470-2045(20)30496-4.


• Zhao S, Zhao H, Lv C, Gong J, Zhang J, Fang W, Li J, Hu X, Ba Y, Xu B, Zhang Y, Fan Y, Li K, Chen X, Yang Z, Shen L, Zhang L. Anticancer drug R&D landscape in China. J Hematol Oncol. 2020 May 13;13(1):51. doi: 10.1186/s13045-020-00877-3.


• Shen L, Guo J, Zhang Q, Pan H, Yuan Y, Bai Y, Liu T, Zhou Q, Zhao J, Shu Y, Huang X, Wang S, Wang J, Zhou A, Ye D, Sun T, Gao Y, Yang S, Wang Z, Li J, Wu YL. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. J Immunother Cancer. 2020 Jun;8(1):e000437. doi: 10.1136/jitc-2019-000437.


• Lu Z, Chen H, Li S, Gong J, Li J, Zou J, Wu L, Yu J, Han W, Sun H, Jiao X, Zhang X, Peng Z, Lu M, Wang Z, Zhang H, Shen L. Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer. J Immunother Cancer. 2020 Aug;8(2):e000374. doi: 10.1136/jitc-2019-000374.


• Lu Z, Chen H, Jiao X, Zhou W, Han W, Li S, Liu C, Gong J, Li J, Zhang X, Wang X, Peng Z, Qi C, Wang Z, Li Y, Li J, Li Y, Brock M, Zhang H, Shen L. Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier. J Immunother Cancer. 2020 Aug;8(2):e000631. doi: 10.1136/jitc-2020-000631.


• Wang Z, Zhao X, Gao C, Gong J, Wang X, Gao J, Li Z, Wang J, Yang B, Wang L, Zhang B, Zhou Y, Wang D, Li X, Bai Y, Li J, Shen L. Plasma-based microsatellite instability detection strategy to guide immune checkpoint blockade treatment. J Immunother Cancer. 2020 Nov;8(2):e001297. doi: 10.1136/jitc-2020-001297.


• Lu M, Zhang P, Zhang Y, Li Z, Gong J, Li J, Li J, Li Y, Zhang X, Lu Z, Wang X, Zhou J, Peng Z, Wang W, Feng H, Wu H, Yao S, Shen L. Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial. Clin Cancer Res. 2020 May 15;26(10):2337-2345. doi: 10.1158/1078-0432.CCR-19-4000.


• Peng Z, Cheng S, Kou Y, Wang Z, Jin R, Hu H, Zhang X, Gong JF, Li J, Lu M, Wang X, Zhou J, Lu Z, Zhang Q, Tzeng DTW, Bi D, Tan Y, Shen L. The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer. Cancer Immunol Res. 2020 Oct;8(10):1251-1261. doi: 10.1158/2326-6066.CIR-19-1014.


• Cao Y, Ma Y, Yu J, Sun Y, Sun T, Shao Y, Li J, Shen L, Lu M. Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide-induced high tumor mutational burden. Cancer Commun (Lond). 2020 Dec;40(12):746-751. doi: 10.1002/cac2.12114.


• Li J, Yuan Y, Yang F, Wang Y, Zhu X, Wang Z, Zheng S, Wan D, He J, Wang J, Ba Y, Bai C, Bai L, Bai W, Bi F, Cai K, Cai M, Cai S, Chen G, Chen K, Chen L, Chen P, Chi P, Dai G, Deng Y, Ding K, Fan Q, Fang W, Fang X, Feng F, Fu C, Fu Q, Gu Y, He Y, Jia B, Jiang K, Lai M, Lan P, Li E, Li D, Li J, Li L, Li M, Li S, Li Y, Li Y, Li Z, Liang X, Liang Z, Lin F, Lin G, Liu H, Liu J, Liu T, Liu Y, Pan H, Pan Z, Pei H, Qiu M, Qu X, Ren L, Shen Z, Sheng W, Song C, Song L, Sun J, Sun L, Sun Y, Tang Y, Tao M, Wang C, Wang H, Wang J, Wang S, Wang X, Wang X, Wang Z, Wu A, Wu N, Xia L, Xiao Y, Xing B, Xiong B, Xu J, Xu J, Xu N, Xu R, Xu Z, Yang Y, Yao H, Ye Y, Yu Y, Yu Y, Yue J, Zhang J, Zhang J, Zhang S, Zhang W, Zhang Y, Zhang Z, Zhang Z, Zhao L, Zhao R, Zhou F, Zhou J, Jin J, Gu J, Shen L. Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition). J Hematol Oncol. 2019 Feb 14;12(1):16. doi: 10.1186/s13045-019-0702-0.


• Zhang C, Qu L, Lian S, Meng L, Min L, Liu J, Song Q, Shen L, Shou C. PRL-3 Promotes Ubiquitination and Degradation of AURKA and Colorectal Cancer Progression via Dephosphorylation of FZR1. Cancer Res. 2019 Mar 1;79(5):928-940. doi: 10.1158/0008-5472.CAN-18-0520.


• Wang J, Xing B, Liu W, Li J, Wang X, Li J, Yang J, Ji C, Li Z, Dong B, Gao J, Shen L. Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis. Theranostics. 2019 May 25;9(12):3485-3500. doi: 10.7150/thno.32033.


• Wang X, Wu WKK, Gao J, Li Z, Dong B, Lin X, Li Y, Li Y, Gong J, Qi C, Peng Z, Yu J, Shen L. Autophagy inhibition enhances PD-L1 expression in gastric cancer. J Exp Clin Cancer Res. 2019 Mar 29;38(1):140. doi: 10.1186/s13046-019-1148-5.


• Liu T, Qin Y, Li J, Xu R, Xu J, Yang S, Qin S, Bai Y, Wu C, Mao Y, Wu H, Ge Y, Shen L. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. Cancer Commun (Lond). 2019 Jun 24;39(1):38. doi: 10.1186/s40880-019-0384-6.


• Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, Song C, Wu H, Eng-Wong J, Kim K, Kang YK. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018 Oct;19(10):1372-1384. doi: 10.1016/S1470-2045(18)30481-9.


• Chen Z, Huang W, Tian T, Zang W, Wang J, Liu Z, Li Z, Lai Y, Jiang Z, Gao J, Shen L. Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer. J Hematol Oncol. 2018 Feb 13;11(1):20. doi: 10.1186/s13045-018-0563-y.


• Liu Z, Chen Z, Wang J, Zhang M, Li Z, Wang S, Dong B, Zhang C, Gao J, Shen L. Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance. J Hematol Oncol. 2018 Aug 29;11(1):109. doi: 10.1186/s13045-018-0651-z.


• Ge S, Xia X, Ding C, Zhen B, Zhou Q, Feng J, Yuan J, Chen R, Li Y, Ge Z, Ji J, Zhang L, Wang J, Li Z, Lai Y, Hu Y, Li Y, Li Y, Gao J, Chen L, Xu J, Zhang C, Jung SY, Choi JM, Jain A, Liu M, Song L, Liu W, Guo G, Gong T, Huang Y, Qiu Y, Huang W, Shi T, Zhu W, Wang Y, He F, Shen L, Qin J. Author Correction: A proteomic landscape of diffuse-type gastric cancer. Nat Commun. 2018 May 8;9(1):1850. doi: 10.1038/s41467-018-04166-z.


• Li Y, Zhang X, Liu D, Gong J, Wang DD, Li S, Peng Z, Li Y, Wang X, Lin PP, Li M, Shen L. Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance. Clin Cancer Res. 2018 Nov 1;24(21):5261-5271. doi: 10.1158/1078-0432.CCR-18-1205.


• Lin X, Chen D, Zhang C, Zhang X, Li Z, Dong B, Gao J, Shen L. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. J Exp Clin Cancer Res. 2018 Jun 28;37(1):129. doi: 10.1186/s13046-018-0790-7.


• Wang X, Hu J, Cao G, Zhu X, Cui Y, Ji X, Li X, Yang R, Chen H, Xu H, Liu P, Li J, Li J, Hao C, Xing B, Shen L. Phase II Study of Hepatic Arterial Infusion Chemotherapy with Oxaliplatin and 5-Fluorouracil for Advanced Perihilar Cholangiocarcinoma. Radiology. 2017 May;283(2):580-589. doi: 10.1148/radiol.2016160572.


• Tejpar S, Shen L, Wang X, Schilsky RL. Integrating biomarkers in colorectal cancer trials in the West and China. Nat Rev Clin Oncol. 2015 Sep;12(9):553-60. doi: 10.1038/nrclinonc.2015.88.


• Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, Park SR, Fujii M, Kang YK, Chen LT. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013 Nov;14(12):e535-47. doi: 10.1016/S1470-2045(13)70436-4.


• Cui Y, Zhang XP, Sun YS, Tang L, Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology. 2008 Sep;248(3):894-900. doi: 10.1148/radiol.2483071407.